# A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

> **NCT01358227** · PHASE1 · COMPLETED · sponsor: **Proacta, Incorporated** · enrollment: 26 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** PR104

## Key facts

- **NCT ID:** NCT01358227
- **Lead sponsor:** Proacta, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358227, "A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01358227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*